Sep, 2021

U.S.A.
News / Corporate
Astellas Recognized Consistently Among Top Companies for Working Parents
Seramount (formerly Working Mother Media) revealed its annual list of the 2021 100 Best Companies today, marking the seventh consecutive year Astellas is ranked as a top company for working moms....
Read More
U.S.A.
News / Corporate
Astellas and MBC BioLabs Announce Future Innovator Prize to Help Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts
Astellas Venture Management LLC (President: Kazunori Maruyama, Ph.D, "AVM"), a wholly-owned venture capital subsidiary of Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.,...
Read More

Aug, 2021

U.S.A.
News / Corporate
Astellas Partners with LabCentral to Help Emerging Biotechs Accelerate Preclinical Scientific Research
Astellas Venture Management LLC (President: Kazunori Maruyama, Ph.D., "AVM"), a wholly-owned venture capital subsidiary of Astellas Pharma Inc., and LabCentral, a launchpad for early-stage...
Read More

Jul, 2021

U.S.A.
News / Corporate
U.S. Food and Drug Administration Expands Indication for PROGRAF® for Prevention of Organ Rejection in Adult and Pediatric Lung Transplant Recipients
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application...
Read More

May, 2021

U.S.A.
News / Corporate
Astellas' XTANDI™ (enzalutamide) Approved by European Commission for Men with Metastatic Hormone-Sensitive Prostate Cancer
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today that the European Commission (EC) has approved an additional indication for the oral...
Read More